热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Alexa Fluor® 700 anti-mouse CD8a Antibody
产品名称：
Alexa Fluor® 700 anti-mouse CD8a Antibody
产品类别：
抗体
产品编号：
100729
产品应用：
100729
[价格]
规格 价格 库存
25µg ￥ 1128 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor? 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  30. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  2. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  3. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  4. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  5. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  6. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  8. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  9. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  10. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  11. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  12. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  13. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  14. Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed
  15. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  16. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  17. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  18. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  19. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  20. Ye M, et al. 2022. Nat Nanotechnol. 17:880. PubMed
  21. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  22. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  23. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  24. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  25. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  26. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  27. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  28. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  29. Ma C, et al. 2016. Nature. 531:253-257. PubMed
  30. Panciera T, et al. 2016. Cell Stem Cell. 19:725-737. PubMed
  31. Nakagawa P, et al. 2017. Physiol Rep. 10.14814/phy2.13084. PubMed
  32. Biancur DE, et al. 2020. Cell Metabolism. 33(1):199-210.e8. PubMed
  33. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  34. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  35. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  36. Bunn P, et al. 2014. J Immunol. 192:3709. PubMed
  37. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  38. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  39. Pérol L, et al. 2016. Nat Commun. 7:13027. PubMed
  40. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  41. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  42. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  43. Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed
  44. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  45. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  46. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  47. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  48. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
  49. Yang Y, et al. 2021. Sci Adv. 7:eabf6290. PubMed
  50. Sobecki M, et al. 2021. Nat Commun. 12:4700. PubMed
  51. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  52. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  53. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  54. Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed
  55. Qiao J, et al. 2019. Cancer Cell. 35:901. PubMed
  56. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  57. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  58. Zhu X et al. 2019. Cell reports. 27(4):1205-1220 . PubMed
  59. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  60. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  61. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  62. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  63. Bronisz–Budzynska I, et al. 2019. Skelet Muscle. 9:22. PubMed
  64. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  65. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  66. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  67. Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed
  68. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  69. Li C, et al. 2018. Cell. 174:285. PubMed
  70. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  71. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  72. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  73. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  74. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  75. Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed
  76. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  77. McPhee C, et al. 2013. J Immunol. 191:4581. PubMed
  78. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  79. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  80. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  81. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  82. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  83. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  84. Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed
  85. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  86. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  87. Gawish R, et al. 2022. Elife. 11:. PubMed
  88. Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed
  89. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  90. Engelbertsen D, et al. 2013. Arterioscler Thromb Vasc Biol. 33:637. PubMed
RRID
AB_493702 (BioLegend Cat. No. 100729) AB_493703 (BioLegend Cat. No. 100730)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线